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Abstract	
Background	
A deceleration in the increase in cancer incidence in children and adolescents has been reported in 
several national and regional studies in Europe. Based on a large database representing 1·3 billion 
person-years over the period 1991–2010, we provide a consolidated report on cancer incidence 
trends at ages 0–19 years. 
Methods	
We invited all population-based cancer registries operating in European countries to participate in 
this population-based registry study. We requested a listing of individual records of cancer cases, 
including sex, age, date of birth, date of cancer diagnosis, tumour sequence number, primary site, 
morphology, behaviour, and the most valid basis of diagnosis. We also requested population counts 
in each calendar year by sex and age for the registration area, from official national sources, and 
specific information about the covered area and registration practices. An eligible registry could 
become a contributor if it provided quality data for all complete calendar years in the period 1991–
2010. Incidence rates and the average annual percentage change with 95% CIs were reported for all 
cancers and major diagnostic groups, by region and overall, separately for children (age 0–14 years) 
and adolescents (age 15–19 years). We examined and quantified the stability of the trends with 
joinpoint analyses. 
Findings	
For the years 1991–2010, 53 registries in 19 countries contributed a total of 180 335 unique cases. 
We excluded 15 162 (8·4%) of 180 335 cases due to differing practices of registration, and 
considered the quality indicators for the 165 173 cases included to be satisfactory. The average 
annual age-standardised incidence was 137·5 (95% CI 136·7–138·3) per million person-years and 
incidence increased significantly by 0·54% (0·44–0·65) per year in children (age 0–14 years) with 
no change in trend. In adolescents, the combined European incidence was 176·2 (174·4–178·0) per 
million person-years based on all 35 138 eligible cases and increased significantly by 0·96% (0·73–
1·19) per year, although recent changes in rates among adolescents suggest a deceleration in this 
increasing trend. We observed temporal variations in trends by age group, geographical region, and 
diagnostic group. The combined age-standardised incidence of leukaemia based on 48 458 cases in 
children was 46·9 (46·5–47·3) per million person-years and increased significantly by 0·66% 
(0·48–0·84) per year. The average overall incidence of leukaemia in adolescents was 23·6 (22·9–
24·3) per million person-years, based on 4702 cases, and the average annual change was 0·93% 
(0·49–1·37). We also observed increasing incidence of lymphoma in adolescents (average annual 
change 1·04% [0·65–1·44], malignant CNS tumours in children (average annual change 0·49% 
[0·20–0·77]), and other tumours in both children (average annual change 0·56 [0·40–0·72]) and 
adolescents (average annual change 1·17 [0·82–1·53]). 
Interpretation	
Improvements in the diagnosis and registration of cancers over time could partly explain the 
observed increase in incidence, although some changes in underlying putative risk factors cannot be 
excluded. Cancer incidence trends in this young population require continued monitoring at an 
international level. 
Funding	
Federal Ministry of Health of the Federal German Government, the European Union's Seventh 
Framework Programme, and International Agency for Research on Cancer. 
Introduction	
Cancer is an important disease burden in children as it is not easily prevented, with known causes 
explaining only a small proportion of cases. In Europe, incidence rates range from 140–170 per 
million person-years (ie, number of incident cases divided by the number of person-years at risk) in 
populations younger than 15 years and from 180–240 per million in those aged 15–19 years.1 
During the past three decades, incidence increased by about 1% per annum for all cancers combined 
and this increase affected most major diagnostic groups, including leukaemias, lymphomas, and 
CNS tumours.2 However, in the past decade, incidence appears to have stabilised overall and for the 
major diagnostic groups in European populations.3, 4, 5, 6, 7, 8, 9, 10 
Research in context 
Evidence before this study 
We searched PubMed with no language restrictions to identify studies published since Jan 1, 2004, 
that investigated cancer incidence trends in children (age 0–14 years) and adolescents (age 15–19 
years) in Europe and other high-income countries, using the search terms ‘child* cancer incidence 
trends’ and ‘adolescen* cancer incidence trends’. Evidence from retrieved studies suggested that 
after a substantial increase in childhood cancer incidence towards the end of the last century, the 
rate of increase has declined in the 2000s. However, the limitations of most of these studies, in 
terms of number of cases or timeframe, might have hampered the full understanding of the 
dynamisms behind the observed trends in this population. 
Added value of this study 
We used all quality data available in Europe for the full calendar years in the period 1991–2010 to 
evaluate incidence patterns and trends in children and adolescents. Overall, incidence continued to 
increase during the study period by 0·5% per year in children and 1·0% per year in adolescents. 
However, we observed some evidence of a deceleration in increasing cancer trends, modulated by 
age group, European region, and diagnostic group. Based on the large scale of all available 
European data, our findings add an authoritative account on the geographical patterns and temporal 
trends of cancer in children and adolescents in Europe. 
Implications of all the available evidence 
The increasing trends might have resulted from improvements in cancer diagnosis or registration in 
this age group, although the influence of other factors cannot be excluded. The paucity of evidence 
of stabilisation of cancer incidence in Europe and the variability of the observed trends support the 
need for continued international monitoring and research into causal mechanisms. 
Leukaemias, lymphomas, and tumours of the CNS represent 70% of all cancers observed in 
European populations younger than 15 years and half of all cancers in those aged 15–19 years1 and 
therefore contribute considerably to the overall incidence. Changing incidence could result from 
numerous factors, including variations in diagnostic capacity, completeness of registration, 
population composition, and exposure to risk factors. Monitoring these trends is important for 
planning health-care delivery and for aetiological research. 
In this study, we documented and interpreted incidence trends in Europe for cancers diagnosed at 
ages 0–19 years using quality-assured population-based cancer registries. We focused on the 20-
year period 1991–2010, assessing the trends separately in children (aged 0–14 years) and 
adolescents (aged 15–19 years), for all cancers combined and for the major diagnostic groups. Our 
results update the Automated Childhood Cancer Information System (ACCIS) studies, extending 
the previously reported period of observation by over a decade.2, 11 
Methods	
Data	acquisition	
We invited all population-based cancer registries operating in European countries (as defined by the 
UN Statistics Division12) and Cyprus to participate in this population-based registry study. We 
requested a listing of individual records of cancer cases, and the population in each calendar year by 
sex and age from official national sources, accompanied by specific information about the 
geographical and administrative area covered and registration practices. 
Information on cancer cases included coded data on sex, age, date of birth, date of diagnosis, 
tumour sequence number, primary site, morphology, behaviour, and the most valid basis of 
diagnosis. Most registries coded tumours according to the International Classification of Diseases 
for Oncology, Third Edition (ICD-O-313) as required, and International Classification of Diseases 
for Oncology, Second Edition14 codes were converted to ICD-O-3 codes. Subsequently, neoplasms 
were classified according to the International Classification of Childhood Cancer, Third Edition 
(ICCC-3).15 We examined individual records for internal consistency,16 verifying unlikely 
combinations of site with morphology, age or sex with tumour type, basis of diagnosis with 
morphology, and rare tumour entities. The proportions of cases microscopically verified, identified 
from death certificate only, or with unknown basis of diagnosis and unspecified morphology 
contributed to data evaluation. The ACCIS Scientific Committee assessed the distribution of new 
cases across years and plausibility of case mix and age distribution. Standardised tables, charts, 
statistics, lists of selected questioned records, and any relevant information provided by the registry 
or known from published sources were discussed at meetings of the ACCIS Scientific Committee, 
who decided on the inclusion of each dataset in the ACCIS database. Only datasets with high-
quality data were eligible for inclusion in the analyses. 
The cancers included in the analyses were all malignant tumours diagnosed during the complete 
calendar years 1991–2010, in people younger than 20 years and resident in the contributing 
registration areas. Several cancer types were excluded because they were not eligible for 
registration in all participating registries or during the whole study period: myelodysplasias (ICD-
O-3 M-codes starting with 998), pilocytic astrocytoma (ICD-O-3 code M-9421), non-melanoma 
skin cancer (ICCC-3 subgroup XIe and XIIb with site code C44), and carcinoid tumour of the 
appendix (ICD-O-3 site code C18.1 and M-8240). 
The data used in this study were submitted and validated during the years 2015–16. Our study 
design was reviewed and approved by the International Agency for Research on Cancer (IARC) 
Ethics Committee on June 17, 2015. 
Dataset	constitution	
An eligible registry could become a contributor if it provided quality data for all complete calendar 
years in the 20-year period 1991–2010. The 53 contributing registries in 19 countries (appendix p 2) 
included nine paediatric registries. The paediatric registries collected and provided data for those 
aged 0–14 years, and the other cancer registries and the paediatric registry of Belarus provided data 
for the full target age range (0–19 years). The French national paediatric registry registered 
haematological malignancies only. 
Some populations in France, Germany, Italy, Spain, Switzerland, and the UK were covered by both 
paediatric and general cancer registries. To avoid double counting of cases in two registries while 
using the maximum number of cases for analyses in these populations, we allocated each registry to 
one or more datasets (appendix p 2). We built three datasets—one with 39 registries contributing to 
the analyses of all cancers, CNS tumours, and other tumours in ages 0–14 years, a second with 32 
registries contributing to the analyses of leukaemia and lymphoma in ages 0–14 years, and a third 
with 45 registries contributing to all the analyses of those aged 15–19 years. The first and second 
datasets (ages 0–14 years) differed only in the contribution from France; the analyses of all cancers 
and CNS tumours used a dataset that included data from the French general cancer registries, while 
the leukaemia and lymphoma dataset included data from the French national paediatric registry of 
haematological malignancies. The French national registry increased the person-years by ten times 
and provided 11 770 more haematological malignancies compared with the combined contribution 
of the French regional registries. 
Subnational numbers of cases and person-years were pooled to produce national cancer incidence 
and countries were further pooled into four European regions (appendix p 2) according to UN 
definitions.12 The person-years available in each region are shown in the appendix (p 3). 
Statistical	analysis	
The number of incident cases in the covered areas of the participating registries during the study 
period determined our sample size. Incidence was calculated as the number of cases divided by the 
number of person-years in the categories of geographical area, sex, age, and diagnostic group for 
the given 20-year period and expressed per million person-years. As the age distribution of 
population at risk differs between countries and over time, we adjusted the reported incidence for 
the age range 0–14 years for age via direct standardisation using weights 12, 10, and 9 for the three 
age groups 0–4 years, 5–9 years, and 10–14 years, respectively.17 We also calculated 95% CIs. As 
each combination of calendar year, sex, and age group had a positive person-years count, we 
encountered no missing data. 
To graphically portray incidence trends for all cancers, we plotted observed incidence against 
calendar year for each country, and the rates for the four European regions were smoothed using a 
locally weighted regression18 of the incidence on year. 
To assess the average annual percentage change, we fit the natural logarithm of the incidence with 
year using generalised linear regression models adjusting for age group and region, as appropriate. 
We quantified changes in incidence as the average annual percentage change, with corresponding 
95% CIs. The null hypothesis corresponded to no change in the annual rate, which was equivalent 
to 0 lying within the 95% CI for the average annual percentage change. We analysed each cancer 
category, overall and by European region, using Stata (version 14). We examined incidence trends 
for changes during the study period using Joinpoint Regression Program (version 4.1.0) applied to 
the log rates, separately for the age groups 0–14 years and 15–19 years in the total dataset, and in 
each cancer category, overall and by region. The null hypothesis assumed the annual percentage 
change was constant throughout the study period. We used the permutation test19 to determine the 
number of joinpoints, by default set to a maximum of three for Europe and five for analyses 
adjusted for region. Where joinpoints were detected, we reported the annual percentage change with 
corresponding 95% CIs for each of the linear segments identified between two significant 
joinpoints. 
Role	of	the	funding	source	
The funders of the study external to the collaborating institutions had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. MC, MMF, and ES-F had full 
access to all the data used in the study. The corresponding author had final responsibility for the 
decision to submit for publication. 
Results	
During the full calendar years of the period 1991–2010, the 53 registries contributed 1·3 billion 
person-years and 180 335 unique cases. 15 162 (8·4%) of 180 335 cases were excluded, and the 
proportion of excluded cases varied slightly between age groups and regions. We considered the 
quality indicators for the 165 173 included cases to be satisfactory (appendix p 3). In 2010, the 
available population at risk represented 53·2 million (46·6%) of 114·1 million of the European 
population aged 0–14 years and 9·8 million (22·6%) of 43·2 million aged 15–19 years, with 
reference to UN population estimates.20 In western Europe, coverage of the childhood population 
was almost complete for haematological malignancies (27·9 million [93·3%] of 29·9 million), and 
17·5 million (58·5%) of 29·9 million were covered for the other malignancies, while 2·1 million 
(20·1%) of 10·6 million adolescents were covered (appendix p 3). 
We included all 118 265 eligible cases in patients aged 0–14 years in our analyses of incidence of 
all cancers. The average annual age-standardised incidence was 137·5 (95% CI 136·7–138·3) per 
million person-years and incidence increased significantly by 0·54% (0·44–0·65) per year on 
average (table 1), with no break in the time trend. There was a large decrease in incidence for the 
national registry of Belarus, contributing to the regional pattern (figure 1). The large fluctuation of 
annual incidence in Iceland was due to small population size and did not visibly affect the shape of 
the regional curve (figure 1). The trend in the east was split into two segments, both with non-
significant trends (figure 2). 
Table 1. Number of new cases, world age‐standardised incidence per million person‐years, and average annual percentage change by diagnostic 
category in children aged 0–14 years, by European region, 1991–2010 
All cancers Leukaemia Lymphoma Malignant CNS tumours Other cancers 
 Cases 
Incidence 
per 
million 
person-
years 
(95% CI) 
Annual 
change 
(95% 
CI) 
Cases 
Incidence 
per 
million 
person-
years 
(95% CI) 
Annual 
change 
(95% 
CI) 
Cases
Incidence 
per 
million 
person-
years 
(95% CI)
Annual 
change 
(95% 
CI) 
Cases
Incidence 
per 
million 
person-
years 
(95% CI)
Annual 
change 
(95% 
CI) 
Cases 
Incidence 
per 
million 
person-
years 
(95% CI)
Annual 
change 
(95% 
CI) 
East 19 274 
137·9 
(135·9 to 
139·9) 
0·50% 
(0·21 to 
0·79) 
5721 
42·6 
(41·5 to 
43·8) 
1·00% 
(0·44 to 
1·55) 
2652 
17·1 
(16·5 to 
17·8) 
−1·32% 
(−2·08 
to 
−0·56) 
3367 
23·6 
(22·8 to 
24·4) 
0·34% 
(−0·32 
to 1·01) 
7534 
54·5 
(53·3 to 
55·8) 
0·72% 
(0·21 to 
1·23) 
North 34 339 
131·5 
(130·1 to 
132·9) 
0·40% 
(0·16 to 
0·64) 
12 015 
47·0 
(46·1 to 
47·8) 
0·59% 
(0·19 to 
1·00) 
3848 
13·5 
(13·0 to 
13·9) 
0·74% 
(0·00 to 
1·48) 
5996 
22·7 
(22·1 to 
23·2) 
−0·20% 
(−0·58 
to 0·19) 
12 480 
48·4 
(47·6 to 
49·3) 
0·41% 
(−0·00 
to 0·83)
South 14 450 
149·9 
(147·4 to 
152·3) 
0·40% 
(0·07 to 
0·72) 
4472 
47·3 
(45·9 to 
48·7) 
0·68% 
(0·17 to 
1·18) 
2137 
20·4 
(19·5 to 
21·2) 
0·29% 
(−0·54 
to 1·11)
2317 
23·9 
(22·9 to 
24·8) 
−0·44% 
(−1·24 
to 0·37) 
5524 
58·3 
(56·8 to 
59·9) 
0·57% 
(0·06 to 
1·08) 
West 50 202 
138·2 
(136·9 to 
139·4) 
0·70% 
(0·52 to 
0·88) 
26 250 
47·8 
(47·2 to 
48·3) 
0·59% 
(0·37 to 
0·82) 
9821 
15·8 
(15·5 to 
16·1) 
0·44% 
(0·08 to 
0·81) 
7733 
21·0 
(20·5 to 
21·4) 
1·35% 
(0·79 to 
1·93) 
18 168 
51·2 
(50·5 to 
52·0) 
0·62% 
(0·36 to 
0·89) 
Europe 118 265 
137·5 
(136·7 to 
138·3) 
0·54% 
(0·44 to 
0·65) 
48 458 
46·9 
(46·5 to 
47·3) 
0·66% 
(0·48 to 
0·84) 
18 458
15·8 
(15·6 to 
16·0) 
0·26% 
(−0·01 
to 0·54)
19 413
22·2 
(21·9 to 
22·6) 
0·49% 
(0·20 to 
0·77) 
43 706 
51·7 
(51·2 to 
52·2) 
0·56% 
(0·40 to 
0·72) 
 
We investigated incidence for four diagnostic groups in patients aged 0–14 years (table 1, figure 2, 
appendix p 4), and included all eligible cases. The combined age-standardised incidence of 
leukaemia based on 48 458 cases in patients aged 0–14 years was 46·9 (95% CI 46·5–47·3) per 
million person-years and increased by 0·66% (0·48–0·84) per year, with no change in slope. We 
observed an increase in each region, although only during the first decade in the north. The overall 
age-standardised incidence of lymphoma was 15·8 (15·6–16·0) per million person-years (based on 
18 458 cases) and varied modestly by region. Incidence increased in the west and decreased in the 
east, and we detected no change in the slopes. The overall age-standardised incidence of malignant 
CNS tumours (19 413 cases) of 22·2 (95% CI 21·9–22·6) per million person-years was observed to 
rise at 0·49% (0·20–0·77) per annum with no joinpoints; by region, we observed an increasing trend 
only in the west, as the rates were stable in the three other regions. 
In patients aged 0–14 years, the combined incidence of all 43 706 other cancers increased in Europe 
overall and in all regions except the north. In joinpoint analysis, the European trend increased only 
over the first few years, similar to the trend in the west (figure 2). 
In adolescents (aged 15–19 years), the combined European incidence was 176·2 (95% CI 174·4–
178·0) per million person-years based on all 35 138 eligible cases and incidence increased by 
0·96% (95% CI 0·73–1·19) per year in the period 1991–2010 (table 2), although no significant 
change in trend was seen in the second decade (figure 3). We investigated incidence trends by 
country and region, and regional trends by diagnostic group (figure 4, appendix p 5). In addition to 
large variations due to small numbers of cases for some countries, we observed a large range in 
incidence (between around 140 and 240 per million person-years) for Belarus. The slopes of trends 
in the regions were uneven, except in the south. In the east, a decrease was noted over the time 
segment 1999–2008 (figure 3). 
Table 2. Number of new cases, age‐specific incidence per million person‐years, and average annual percentage change by diagnostic category in 
adolescents aged 15–19 years, by European region, 1991–2010 
All cancers Leukaemia Lymphoma Malignant CNS tumours Other cancers 
 Cases 
Incidence 
per 
million 
person-
years 
(95% CI) 
Annual 
change 
(95% 
CI) 
Cases 
Incidence 
per 
million 
person-
years 
(95% CI) 
Annual 
change 
(95% 
CI) 
Cases
Incidence 
per 
million 
person-
years 
Annual 
change 
(95% 
CI) 
Cases
Incidence 
per 
million 
person-
years 
(95% CI)
Annual 
change 
(95% 
CI) 
Cases 
Incidence 
per 
million 
person-
years 
(95% CI)
Annual 
change 
(95% 
CI) 
East 8041 
169·6 
(165·9 to 
173·4) 
1·23% 
(0·62 to 
1·84) 
1023 21·6 (20·3 to 22·9) 
1·79% 
(0·43 to 
3·17) 
2096 44·2 (42·3 to 46·1) 
0·68% 
(0·10 to 
1·26) 
749 15·8 (14·7 to 16·9) 
−0·09% 
(−1·23 
to 1·07) 
4173 88·0 (85·4 to 90·7) 
1·65% 
(0·77 to 
2·54) 
North 15 207 
167·2 
(164·5 to 
169·8) 
0·62% 
(0·28 to 
0·96) 
2192 24·1 (23·1 to 25·1) 
0·08% 
(−0·62 
to 0·78)
3981 43·8 (42·4 to 45·1) 
0·82% 
(0·12 to 
1·52) 
1358 14·9 (14·1 to 15·7) 
−0·91% 
(−2·48 
to 0·68) 
7676 84·4 (82·5 to 86·3) 
0·97% 
(0·65 to 
1·28) 
South 3941 
197·0 
(190·8 to 
203·1) 
1·78% 
(1·36 to 
2·20) 
501 25·0 (22·8 to 27·2) 
2·03% 
(0·66 to 
3·42) 
1244 62·2 (58·7 to 65·6) 
2·13% 
(1·26 to 
3·01) 
288 14·4 (12·7 to 16·1) 
0·94% 
(−0·71 
to 2·62) 
1908 95·4 (91·1 to 99·6) 
1·61% 
(0·80 to 
2·42) 
West 7949 
193·7 
(189·4 to 
197·9) 
1·08% 
(0·72 to 
1·43) 
986 24·0 (22·5 to 25·5) 
1·35% 
(0·33 to 
2·38) 
2125 51·8 (49·6 to 54·0) 
1·59% 
(0·67 to 
2·52) 
588 14·3 (13·2 to 15·5) 
−0·10% 
(−1·43 
to 1·25) 
4250 
103·5 
(100·4 to 
106·6) 
0·95% 
(0·51 to 
1·39) 
Europe 35 138 
176·2 
(174·4 to 
178·0) 
0·96% 
(0·73 to 
1·19) 
4702 23·6 (22·9 to 24·3) 
0·93% 
(0·49 to 
1·37) 
9446 47·4 (46·4 to 48·3) 
1·04% 
(0·65 to 
1·44) 
2983 15·0 (14·4 to 15·5) 
−0·40% 
(−1·19 
to 0·39) 
18 007 90·3 (89·0 to 91·6) 
1·17% 
(0·82 to 
1·53) 
 
For adolescents, the overall incidence of leukaemia was 23·6 (95% CI 22·9–24·3) per million 
person-years (based on all 4702 eligible cases) and varied little between regions (table 2). Incidence 
increased except in the north, where it was fairly stable, resulting in an average annual change of 
0·93% (0·49–1·37). No change in the slopes was detected. Lymphoma (9446 cases) occurred more 
frequently than did leukaemia (4702 cases) or malignant CNS tumours (2983 cases) in adolescents 
compared with children (table 2), and the overall incidence of 47·4 (46·4–48·3) per million person-
years varied moderately by region. An increase in incidence was observed for all European data 
combined and in all European regions investigated. Changes in this trend were detected in the east 
and west, where the increase was limited to the second and first half of the study period, 
respectively (figure 3). The overall age-specific incidence of malignant CNS tumours was 15·0 
(14·4–15·5) per million person-years. Incidence was stable overall and in the four defined regions 
(figure 3), with no change in the slopes. 
The overall rate for all other cancers in adolescents (18 007 cases) was 90·3 per million. The 
European avearge annual change of 1·17% (0·82–1·53) differed between three segments—among 
them a significant increase was detected during the first decade only. The pattern of changes in the 
slopes by region was similar to that observed for all cancers (figure 3). 
Discussion	
In this population-based registry study, we reported on cancer incidence trends in the European 
population of children (aged 0–14 years) and adolescents (aged 15–19 years) during the full 
calendar years 1991–2010, thus extending the ACCIS study by 10–132, 11 years of observation. 
The overall incidence for children and adolescents increased significantly over this 20-year period. 
The increase in incidence was not constant by cancer type, region, or over time, and there was a 
suggestion of stabilisation in the trend for all cancers in adolescents in the dataset for the whole of 
Europe (appendix p 6). The most pronounced inter-regional diversities included the decreasing 
incidence of childhood lymphomas in the east (compared with stable or increasing incidence in the 
other regions), an increase in the incidence of childhood CNS tumours in the west (compared with 
little change observed in the other regions), and the stable incidence of leukaemia in adolescents in 
the north (relative to increasing incidence in the other regions). 
Although our results are largely confirmatory and incremental from previous findings, a major 
strength of our study is its large size, which permits detection of a moderate rate of increase of 
0·5% per year in the age group 0–14 years. Data from large paediatric cancer registries helped to 
increase the coverage and creation of a specific dataset for childhood haematological malignancies 
enlarged the relevant person-years in the west (583·8 million) by 53% compared with data available 
for other neoplasms (380·5 million). We examined the trends separately in children and adolescents 
to allow for variations in trends between these populations with a different case mix. 
We validated the quality and completeness of the data from the included registries during a 
thorough dataset assessment. We consider our results to provide the best available estimates of 
incidence trends in the European population of children and adolescents for 1991–2010. 
A limitation of our study is the variable coverage of the regions, which might affect the 
representativeness of the incidence at the national and European regional levels. The available data 
do not allow speculation on what the incidence would be if coverage was complete—increase of 
coverage and quality of registration is required for a full picture of the cancer burden. Meanwhile, 
by use of all quality information available for the study period, our results maximise the number of 
person-years of comparable data, and provide evidence of changing trends in European populations. 
We excluded several cancer types that are usually included in reports of childhood cancer incidence 
from our analyses. The excluded cancer types are classified by the ICCC-314 and contribute to the 
total cancer burden, and it is therefore preferable that they are registered. In particular, exclusion of 
non-malignant CNS tumours might have shaped the observed trends. We plan to examine this 
assumption in a focused analysis of trends of all CNS tumours, by behaviour and diagnostic 
subgroup, and by considering the differences and changes in coding and their reportability. 
Our reported total incidence was 5% to 15% lower (depending on the region) than in another report 
assessing the period 2001–10.1 This disparity is explained by the exclusion of several groups of 
neoplasms from our study and the period starting one decade earlier, which would, in the presence 
of an increasing trend, result in a lower overall rate. 
The overall average annual change of 0·54% in children aged 0–14 years is lower than the 1% 
reported by an ACCIS study based on diagnoses in the 1970s through to the 1990s2 or for the period 
1978–97,21 and might indicate a deceleration in the increase of cancer incidence, although the 
registry datasets included differ somewhat between the studies. A lower rate of increase could 
suggest the end of an improvement in reporting, but might also reflect reduced reporting discipline, 
a change in classification of cancers, or other factors. Cancer-specific studies might provide more 
precise interpretation of these trends. 
Studies in European populations of smaller sizes reported stabilising of cancer incidence in children 
overall and in the three major diagnostic groups.3, 4, 5, 6, 7, 8, 9, 10 By contrast, data collected in 
the longstanding registries of the Surveillance, Epidemiology, and End Results (SEER) Program 
suggest continued minor increases in overall childhood cancer incidence over the most recently 
assessed period 1995–2014,22 consistent with our study. In adolescents aged 15–19 years, varying 
incidence trends were observed in different European populations for leukaemia, lymphoma, or 
CNS tumours.3, 4, 7 As for the SEER data,22 our study found an increase in overall cancer 
incidence and leukaemia and lymphoma incidence, but no change in trends for malignant CNS 
tumours. A large US study23 reported stable incidence over the period 2001–09 overall and for the 
three major diagnostic groups in the population younger than 20 years. We identified changes in 
overall trends that provide some evidence of a deceleration of time trends during the most recent 
years of our study, along with varying patterns across age groups, regions, and cancer types, 
although significant joinpoints should not be taken to imply abrupt changes in underlying trends in 
risk.19 The variability we found warrants continued monitoring of incidence patterns in large 
populations over long periods, as trends that are not significant over short intervals might result in 
significant increases over a longer timeframe, and grouping smaller populations with no trend could 
yield a significant change in a pooled dataset. These considerations might also explain the 
discrepancy in the measured rate of change between our study and smaller European datasets.3, 4, 
5, 6, 7, 8, 9, 10 
Kroll and colleagues24 have linked the increase in childhood cancer incidence in Great Britain with 
advances in diagnostic technology and improved cancer registration, because of the concurrence of 
a step increase in leukaemia and non-CNS solid tumour incidence in 2002 with a registration plan 
enacted in 2001. Similarly, the rise in the incidence of CNS tumours in 1992 coincided with the 
introduction of innovative methods of diagnosis. As a result, childhood cancer might have been 
under-reported in Great Britain during parts of the period assessed in this study. Although we are 
not aware of similar studies in other countries, analogous effects on childhood cancer incidence 
cannot be excluded elsewhere in Europe and could have affected our results. 
The gradual convergence of environmental factors, lifestyle, and health services across Europe 
might have contributed to the similarities in incidence trends across the regions, although such 
changes will probably have less of an effect on cancer in childhood than in older age. Nevertheless, 
some opposing trends (notably for lymphoma in the east) suggest caution should be taken in 
ascribing the slowly increasing trends exclusively to improved detection, at least before further 
detailed analyses by cancer type, age group, and geographical region are done. 
Overall incidence in children is weighted towards leukaemia, which, in 75% of cases, is the 
precursor B-cell lymphoid leukaemia. The age-specific curve for this cancer type currently peaks 
around age 2–4 years in most high-income countries. With increasing social development over time, 
this peak shifts towards younger ages and becomes more pronounced.2, 25 This change is unlikely 
to be driven by improved registration, which would affect all ages in the same way. The deficit of 
lymphoid leukaemia cases seen in poorer settings can be ascribed in part to underdiagnosis,26, 27 
but inequalities across social strata might also operate through relevant exposures, such as parental 
occupation, diet, or reproduction characteristics.28 Continuous socioeconomic development and 
increasing awareness of primary care practitioners might have contributed to the observed increase 
in leukaemia cases, although reasons for the stabilisation of leukaemia incidence in northern Europe 
are unclear. 
Incidence of lymphoma was relatively high compared with incidence of leukaemia in children in 
eastern Europe. Considering the likely infectious origin of lymphoma at young ages,29 our observed 
decreasing incidence could be attributed to elimination of certain viral exposures. Furthermore, 
diagnosis of lymphoma might be delayed until older ages, especially if the decreasing trend in 
children is accompanied by an increasing trend in adolescents, as seen in the east over the second 
decade. Possible selective under-reporting could also be considered, as the incidence of leukaemia 
and other cancers continues to increase in children in the east. The high incidence in southern 
Europe is consistent with previous reports of possible environmental exposures.30 A further 
assessment of lymphoma trends by diagnostic subgroups, narrower age groups, and sex could help 
provide a more specific explanation of the observed temporal changes. 
The stability of malignant CNS tumour incidence in adolescents is encouraging, although drawing 
firm conclusions should be postponed until incidence trends are examined using data that include 
non-malignant tumours in the populations in which these are ascertained completely to exclude the 
possible effect of changes in classification of tumours. In children, because of the shown persisting 
increase in incidence in malignant CNS tumours, and the exclusion of non-malignant tumours—
specifically pilocytic astrocytoma—from our analyses, a further detailed assessment is warranted, 
especially considering the poor outcome for such tumours. 
The trends for all other cancers combined show that the overall increase in incidence is not 
explained solely by changes in the three major groups of childhood and adolescent cancer. This fact 
is especially relevant in adolescents, as many cases are germ cell tumours and carcinomas.1 The 
candidate explanatory groups for the increase in at least a part of the period are thyroid carcinoma,31 
testicular tumours,32 and melanoma.33 In particular, the patterns for Belarus are probably shaped by 
the pronounced increase and later waning of thyroid cancer incidence during the study period, 
reflecting exposure to the radioactive fallout from the Chernobyl accident.34 These observations 
also merit detailed studies. 
In summary, in this study we aimed to provide an overview of cancer incidence trends in children 
and adolescents in Europe, as an introduction to a detailed investigation of patterns and trends and 
their possible determinants by diagnostic group and other subcategories in a concerted series of 
studies. We found a continued increase in cancer incidence in children and adolescents in Europe 
over the 20-year period 1991–2010. The diversity of trends across the regions and tumour groups 
warrants further monitoring and a more detailed assessment of the high-quality data collected by 
cancer registries, by specific tumour types and population subgroups. Whether the observed 
increase in cancer incidence in children and adolescents is due to enhanced discovery of cases or 
changing risk factors, the known frequency of cancer in young people should be considered in 
cancer control programmes. Without an accurate quantification of the possible causes of this 
increase, whether real or artifactual, it is prudent to continue aetiological research into the causes of 
cancer in children and adolescents and to explore possible preventive measures. 
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